PCVX vs. EXEL, RVMD, IBRX, HALO, RGEN, CRSP, KRYS, QGEN, IMVT, and SWTX
Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Exelixis (EXEL), Revolution Medicines (RVMD), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), Repligen (RGEN), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Qiagen (QGEN), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "biological products, except diagnostic" industry.
Vaxcyte (NASDAQ:PCVX) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
In the previous week, Exelixis had 2 more articles in the media than Vaxcyte. MarketBeat recorded 12 mentions for Exelixis and 10 mentions for Vaxcyte. Exelixis' average media sentiment score of 0.76 beat Vaxcyte's score of 0.36 indicating that Exelixis is being referred to more favorably in the news media.
96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 2.9% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Exelixis received 544 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 68.75% of users gave Vaxcyte an outperform vote while only 68.12% of users gave Exelixis an outperform vote.
Exelixis has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Vaxcyte presently has a consensus target price of $78.50, suggesting a potential upside of 5.27%. Exelixis has a consensus target price of $26.13, suggesting a potential upside of 24.94%. Given Exelixis' higher possible upside, analysts plainly believe Exelixis is more favorable than Vaxcyte.
Vaxcyte has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Exelixis has a net margin of 11.10% compared to Vaxcyte's net margin of 0.00%. Exelixis' return on equity of 8.85% beat Vaxcyte's return on equity.
Summary
Exelixis beats Vaxcyte on 12 of the 17 factors compared between the two stocks.
Get Vaxcyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
